ACERAGEN, INC. NONQUALIFIED STOCK OPTION GRANT AGREEMENT GRANTED PURSUANT TO THE 2022 EQUITY INCENTIVE PLANNonqualified Stock Option Grant Agreement • April 13th, 2023 • Aceragen, Inc. • Biological products, (no disgnostic substances) • Delaware
This NONQUALIFIED STOCK OPTION GRANT AGREEMENT (the “Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.) (the “Company”) to [●] (the “Participant”).
AMENDMENT NO. 1 TO EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • April 13th, 2023 • Aceragen, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Amendment No. 1 to Executive Transition and Separation Agreement (this “Agreement”), is entered into as of the date set forth on the signature page below (the “Execution Date”), by and between Vincent Milano (“You”) and Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.), a Delaware corporation (together with its wholly owned subsidiaries and affiliates, the “Company”). You and the Company are collectively referred to as the “Parties” throughout this Agreement.
ACERAGEN, INC. INCENTIVE STOCK OPTION GRANT AGREEMENT GRANTED PURSUANT TO THE 2022 EQUITY INCENTIVE PLANIncentive Stock Option Grant Agreement • April 13th, 2023 • Aceragen, Inc. • Biological products, (no disgnostic substances) • Delaware
This INCENTIVE STOCK OPTION GRANT AGREEMENT (the “Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.) (the “Company”) to [●] (the “Participant”).
ACERAGEN, INC. AMENDED AND RESTATED WARRANT TO PURCHASE COMMON STOCKWarrant Agreement • April 13th, 2023 • Aceragen, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS CERTIFIES THAT, for value received, NOVAQUEST CO-INVESTMENT FUND XV, L.P., having an address at 4208 Six Forks Road, Suite 920 Raleigh, NC 27609, or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from ACERAGEN, INC. (f/k/a Idera Pharmaceuticals, Inc.), a Delaware corporation (the “Company”), having an address at 15 T.W. Alexander Drive, Suite 418, Research Triangle Park, NC 22709, shares of the common stock, par value $0.001 per share, of the Company (the “Common Stock”) on the terms and subject to the conditions set forth below.
AMENDMENT NO. 1 TO EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • April 13th, 2023 • Aceragen, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Amendment No. 1 to Executive Transition and Separation Agreement (this “Agreement”), is entered into as of the date set forth on the signature page below (the “Execution Date”), by and between Daniel Soland (“You”) and Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.), a Delaware corporation (together with its wholly owned subsidiaries and affiliates, the “Company”). You and the Company are collectively referred to as the “Parties” throughout this Agreement.
